GlobeNewsWire
18 Nov 2026, 07:30 UTC · 1h ago
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
Impact · against what's priced in
Olema Oncology's presentation of preclinical data for KAT6A degraders provides a potential new pipeline expansion for ER+/HER2- breast cancer. While positive, the early stage of development means this is a long-term prospect rather than an immediate catalyst.
- OLMA+0.10
No priced-in read yet





